A detailed history of Resources Investment Advisors, Llc. transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Resources Investment Advisors, Llc. holds 18,300 shares of MREO stock, worth $66,429. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,300
Previous 18,300 -0.0%
Holding current value
$66,429
Previous $65,000 15.38%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 02, 2024

SELL
$2.58 - $4.25 $549 - $905
-213 Reduced 1.15%
18,300 $65,000
Q1 2024

May 10, 2024

SELL
$2.3 - $4.05 $894 - $1,575
-389 Reduced 2.06%
18,513 $61,000
Q4 2023

Feb 13, 2024

SELL
$1.19 - $2.42 $8,803 - $17,903
-7,398 Reduced 28.13%
18,902 $43,000
Q3 2023

Nov 14, 2023

SELL
$1.15 - $1.67 $14,676 - $21,312
-12,762 Reduced 32.67%
26,300 $33,000
Q2 2023

Aug 07, 2023

BUY
$0.79 - $1.43 $13,509 - $24,453
17,100 Added 77.86%
39,062 $51,000
Q1 2023

May 10, 2023

BUY
$0.71 - $1.22 $15,593 - $26,793
21,962 New
21,962 $15,000
Q3 2022

Nov 08, 2022

SELL
$0.82 - $1.73 $22,413 - $47,286
-27,333 Reduced 58.54%
19,362 $17,000
Q2 2022

Aug 08, 2022

BUY
$0.33 - $1.69 $858 - $4,394
2,600 Added 5.9%
46,695 $52,000
Q1 2022

May 05, 2022

BUY
$1.04 - $1.7 $334 - $547
322 Added 0.74%
44,095 $49,000
Q4 2021

Feb 23, 2022

BUY
$1.51 - $2.59 $11,672 - $20,020
7,730 Added 21.45%
43,773 $70,000
Q3 2021

Nov 05, 2021

BUY
$2.2 - $3.17 $50,694 - $73,046
23,043 Added 177.25%
36,043 $87,000
Q2 2021

Aug 09, 2021

BUY
$2.94 - $4.08 $38,220 - $53,040
13,000 New
13,000 $41,000

Others Institutions Holding MREO

About Mereo Biopharma Group plc


  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $454M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track This Portfolio

Track Resources Investment Advisors, Llc. Portfolio

Follow Resources Investment Advisors, Llc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Resources Investment Advisors, Llc., based on Form 13F filings with the SEC.

News

Stay updated on Resources Investment Advisors, Llc. with notifications on news.